Download Full eBooks in PDF
How The Medicaid Rebate On Prescription Drugs Affects Pricing In The Pharmaceutical Industry Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of How The Medicaid Rebate On Prescription Drugs Affects Pricing In The Pharmaceutical Industry book. This book definitely worth reading, it is an incredibly well-written.
Author : Anonim
Publisher : Unknown
Page : 74 pages
File Size : 45,8 Mb
Release : 1996
Category : Medicaid
ISBN : UOM:39015043099194
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,Committee on Ensuring Patient Access to Affordable Drug Therapies
Publisher : National Academies Press
Page : 235 pages
File Size : 43,5 Mb
Release : 2018-03-01
Category : Medical
ISBN : 9780309468084
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author : United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment
Publisher : Unknown
Page : 342 pages
File Size : 46,7 Mb
Release : 1992
Category : Law
ISBN : STANFORD:36105063132240
Author : Anna Cook
Publisher : Unknown
Page : 86 pages
File Size : 49,5 Mb
Release : 1994
Category : Drugs
ISBN : PURD:32754064458072
Author : Sarah F. Jaggar
Publisher : Unknown
Page : 12 pages
File Size : 45,8 Mb
Release : 1996
Category : Drugs
ISBN : UOM:39015048868817
Author : United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health
Publisher : Unknown
Page : 112 pages
File Size : 54,5 Mb
Release : 2005
Category : Business & Economics
ISBN : STANFORD:36105063581826
Author : Anonim
Publisher : U.S. Government Printing Office
Page : 94 pages
File Size : 48,6 Mb
Release : 1998
Category : Business & Economics
ISBN : PURD:32754071785707
Author : Anonim
Publisher : Unknown
Page : 234 pages
File Size : 47,7 Mb
Release : 2000
Category : Drugs
ISBN : STANFORD:36105028431273
On October 25,1999, the President directed the Secretary of Health and Human Services to study prescription drug costs and trends for Medicare beneficiaries. He asked that the study investigate: price differences for the most commonly used drugs for people with and without coverage; drug spending by people of various ages, as a percentage of income and of total health spending; and trends in drug expenditures by people of different ages, as a percentage of income and of total health spending. This report is the Department's response to that request. It represents the work of individuals and agencies throughout the Department, including the Agency for Healthcare Research and Quality (AHRQ), the Food and Drug Administration (FDA), the Health Care Financing Administration (HCFA), and the Office of the Assistant Secretary for Planning and Evaluation (ASPE).
Author : Institute of Medicine,Board on Health Sciences Policy,Committee on Accelerating Rare Diseases Research and Orphan Product Development
Publisher : National Academies Press
Page : 442 pages
File Size : 52,9 Mb
Release : 2011-04-03
Category : Medical
ISBN : 9780309158060
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
Author : Andrew M. Jones
Publisher : Edward Elgar Publishing
Page : 585 pages
File Size : 44,5 Mb
Release : 2006-03-01
Category : Medical
ISBN : 9781845428914
This Companion is a timely addition. . . It contains 50 chapters, from 90 contributors around the world, on the topical and policy-relevant aspects of health economics. . . there is a balanced coverage of theoretical and empirical materials, and conceptual and practical issues. . . I have found the Companion very useful. Sukhan Jackson, Economic Analysis and Policy This encyclopedic work provides interested readers with an authoritative and comprehensive overview of many, if not all, of the current research issues in health economics. Highly recommended. Upper-level undergraduates and above. R.M. Mullner, Choice The aim of The Elgar Companion to Health Economics is to take an audience of advanced undergraduates, postgraduates and researchers to the frontier of research in health economics, by providing them with short and easily readable introductions to key topics. The volume brings together 50 chapters written by more than 90 leading international contributors. The contributions to the Companion are concise and focus on specific concepts, methods and key evidence. The Companion is a comprehensive and authoritative original reference volume covering theoretical and empirical issues in health economics with a balanced range of material on equity and efficiency in health care systems, health technology assessment and issues of concern for low and middle income countries. It is organised into two broad sections. The first deals with the economics of population health and of health care systems, analysed with both equity and efficiency goals in mind. The second covers the conceptual and practical issues that arise in the evaluation of health care technologies: most often applied to pharmaceuticals but also relevant for other interventions. Many of the contributions address topical and policy-relevant issues including: the economic causes of the growth of obesity in the West, the link between illicit drug use and crime, the consequences of leaving people uninsured against the costs of health care, the impact of globalisation on the international trade in health care services, the role of informal payments in many health care systems, what equal treatment for equal needs means in practice, whether direct-to-consumer advertising of pharmaceuticals is desirable, and how economic evidence is influencing the way that new technologies are made available to patients. Other chapters stress the research done by health economists to develop theoretical models and empirical methods that illuminate the workings of health care systems.
Author : Anna Cook,Andrew Stocking
Publisher : Unknown
Page : 48 pages
File Size : 47,9 Mb
Release : 2014-09-03
Category : Electronic
ISBN : 1457856638
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In FY 2013, Medicare Part D covered 39 million people. The federal government spent $59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was $50 billion, which represented 10% of net federal spending for Medicare. A combination of broader trends in the prescription drug market and lower-than-expected enrollment in Part D has contributed to much lower spending for the program than projected when the MMA became law in 2003. This report examines the federal budgetary cost and competitive design of Medicare Part D and compares Medicare Part D and Medicaid Fee for Service. Figures and tables. This is a print on demand report.
Author : Robin Feldman
Publisher : Cambridge University Press
Page : 203 pages
File Size : 41,5 Mb
Release : 2023-10-31
Category : Law
ISBN : 9781009432948
Examines the pharmaceutical industry to expose how higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines.
Author : Anonim
Publisher : DIANE Publishing
Page : 380 pages
File Size : 45,6 Mb
Release : 1993
Category : Drugs
ISBN : 0788104683
Analyzes the costs, risks, and economic rewards of pharmaceutical R&D and the impact of public policy on both costs and returns. Examines the rapid increase in pharmaceutical R&D that began in the 1980s in the light of trends in science, technology, drug discovery, and health insurance coverage; Government regulation; product liability; market competition; Federal tax policy; and Federal support of prescription drug research. 12 appendices, including a glossary of terms.
Author : United States. Social and Rehabilitation Service
Publisher : Unknown
Page : 462 pages
File Size : 47,8 Mb
Release : 1975
Category : Medicaid
ISBN : STANFORD:36105214593894
Author : United States. Congress. House. Committee on Oversight and Government Reform
Publisher : Unknown
Page : 192 pages
File Size : 52,5 Mb
Release : 2010
Category : Business & Economics
ISBN : PURD:32754081265476
